Use filters to refine the search results.
Results 1-4 of 4
|23-Oct-2015||Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer||Bowtell, DD; Boehm, S; Ahmed, AA; Aspuria, P-J; Bast, RC, et al|
|23-Mar-2015||The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma||Stronach, EA; Cunnea, P; Turner, C; Guney, T; Aiyappa, R, et al|
|1-Oct-2015||Dose-finding quantitative F-18-FDG PET imaging study with the oral pan-AKT inhibitor GSK2141795 in patients with gynecologic malignancies||Gungor, H; Saleem, A; Babar, S; Dina, R; El-Bahrawy, MA, et al|
|19-Oct-2015||A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway||Cheraghchi-Bashi, A; Parker, CA; Curry, E; Salazar, J-F; Gungor, H, et al|